Scholars Central

Conference abstractPublished 2014

Pioglitazone vs Voglibose on glycemic control study in type II diabetes in Indian population

Authors: Premanidhi Panda

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Introduction: Diabetes mellitus, often simply referred to as diabetes?is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced. Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagons secretion. It is with both Micro vascular & macro vascular complications. Type II diabetes is a progressive disease. It requires two to three drug combinations produce good effects and less side effects. Therefore these two drugs taken into consideration like Pioglitazone and Voglibose. It shows good glycemic control FBS, 2hr PPBS & HbA1C and Cholesterol and Triglyceride. Particularly study has been seen whose Blood sugar was not controlled by Glimiperide and Metformin. Intent: Intent of the study done By Author from 2012 February to July 2012over a period of 6Months over 200 Cases Type ?II Diabetes shows tremendous result in reduction of blood sugar, Maintenance of Blood sugar very stable as compared to with Pioglitazone or voglibose who are under Uncontrolled blood sugar with Glimeperide and Metformin. It shows good glycemic control Constant maintenance of HBA1C 5. 8 to 6. 5 range. Reduction in Lipid Profile Serum Cholesterol , Serum Triglyceride, LDL& VLDL. Method:-Two randomised group within the age group 30-70Years of Type II either sex given Pioglitazone and Voglibose with the FBS> 130mg/dl, HbA1C between 7-10 selected at random. All the parameters like FBS, 2hr PPBS, HbA1c, Lipid profile cholesterol, Triglyceride, LDL & VLDL observed time to time. It was observed within 6months FBS, 2hr PPBS, HbA1c, Cholesterol , TG, LDL&VLDL was greatly effected with Pioglitazone than Voglibose. Non of the patient complaint anything with pioglitazone except weight gain. With Voglibose few patient shows Flatulence, abdominal distension, Increase in LFT. Conclusion:-In my study shows Pioglitazone has got more effective drug than Voglibose Without any side effect. Better control of FBS, 2hr PPBS, Lipid Profile. In my study shows Pioglitazone has got minimal sideeffects than voglibose. ****I HAVE GOT >40, 000 Diabetes Patients. More than 20, 000Patients are under Pioglitazone since 2009. . Even I had given my view to Govt of India not to banned Pioglitazone.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Premanidhi Panda”